Orthofix Medical (OFIX) Stock Price, News & Analysis

Company Overview

Orthofix Medical Inc. is a global medical device company specializing in spine and orthopedic solutions. The company develops, manufactures and markets devices designed to treat spinal disorders, musculoskeletal trauma, and bone growth. Its core offerings span advanced spinal implant systems, growth stimulation therapies and biologic products aimed at accelerating fusion and healing in patients with degenerative spinal conditions and complex fractures.

In its spine business, Orthofix provides a comprehensive portfolio that includes minimally invasive and open surgical fixation systems, interbody fusion devices and dynamic stabilization technologies. The company’s bone growth stimulation products leverage pulsed electromagnetic field (PEMF) technology to promote bone repair in cases of delayed union, nonunion fractures and spinal fusion procedures. Orthofix also offers a range of external fixation and bracing solutions for orthopedic trauma and deformity correction, catering to both acute injury management and long-term rehabilitative care.

With a presence in over 70 countries, Orthofix serves hospitals, surgery centers and orthopedic practices across North America, Europe, Latin America and the Asia-Pacific region. The company operates manufacturing facilities in the United States and Europe, complemented by a direct sales force and distribution partnerships that extend its reach into emerging markets. Orthofix’s commitment to clinical research and regulatory compliance underpins its global expansion strategy and supports ongoing product innovation.

Founded in 1980 and headquartered in Lewisville, Texas, Orthofix has built a track record of strategic growth through targeted product development and select acquisitions. Under the leadership of President and Chief Executive Officer Brad Mason, the company continues to invest in R&D, new technology platforms and collaborative programs with healthcare providers. Orthofix remains focused on enhancing patient outcomes and delivering value to stakeholders through its specialized orthopedics and spine solutions.

Key Stats

• Today's Range: $10.95 to $11.40
• 50-Day Range: $10.34 to $13.79
• 52-Week Range: $10.24 to $20.73
• Volume: 270,040 shs
• Average Volume: 290,026 shs
• Market Capitalization: $442.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.50
• Consensus Rating: Buy

Orthofix Medical Stock Analysis - MarketRank™

Orthofix Medical scored higher than 66% of companies evaluated by MarketBeat, and ranked 325th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Orthofix Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Orthofix Medical has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Orthofix Medical are expected to grow in the coming year, from ($2.81) to ($1.32) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Orthofix Medical is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Orthofix Medical is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Orthofix Medical has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.73% of the float of Orthofix Medical has been sold short.

Short Interest Ratio / Days to Cover

Orthofix Medical has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Orthofix Medical has recently increased by 27.97%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Orthofix Medical does not currently pay a dividend.

Dividend Growth

Orthofix Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.73% of the float of Orthofix Medical has been sold short.

Short Interest Ratio / Days to Cover

Orthofix Medical has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Orthofix Medical has recently increased by 27.97%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 1.20

News Sentiment

Orthofix Medical has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Orthofix Medical this week, compared to 8 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Orthofix Medical insiders have bought 1,450.32% more of their company's stock than they have sold. Specifically, they have bought $1,394,858.00 in company stock and sold $89,972.00 in company stock.

Percentage Held by Insiders

Only 1.30% of the stock of Orthofix Medical is held by insiders.

Percentage Held by Institutions

89.76% of the stock of Orthofix Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OFIX Stock Analysis - Frequently Asked Questions

How have OFIX shares performed this year?

Orthofix Medical's stock was trading at $17.46 at the start of the year. Since then, OFIX stock has decreased by 35.3% and is now trading at $11.29.

How were Orthofix Medical's earnings last quarter?

Orthofix Medical Inc. (NASDAQ:OFIX) posted its quarterly earnings data on Thursday, November, 7th. The medical device company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.57. The medical device company had revenue of $196.61 million for the quarter, compared to the consensus estimate of $196.60 million. Orthofix Medical had a negative net margin of 17.78% and a negative trailing twelve-month return on equity of 28.15%.
Read the conference call transcript.

How do I buy shares of Orthofix Medical?

Shares of OFIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Orthofix Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Orthofix Medical investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 7/09/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:OFIX
• CIK: 884624
• Web: www.orthofix.com
• Phone: (214) 937-2000
• Fax: 599 9 461 6978
• Employees: 1,616
• Year Founded: 1980

Price Target and Rating

• Average Price Target for Orthofix Medical: $21.50
• High Price Target: $24.00
• Low Price Target: $16.00
• Potential Upside/Downside: +90.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$126 million
• Net Margins: -17.78%
• Pretax Margin: -17.51%
• Return on Equity: -28.15%
• Return on Assets: -16.51%

Debt

• Debt-to-Equity Ratio: 0.38
• Current Ratio: 2.71
• Quick Ratio: 1.50

Sales & Book Value

• Annual Sales: $799.49 million
• Price / Sales: 0.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.07 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 39,180,000
• Free Float: 38,672,000
• Market Cap: $442.34 million
• Optionable: Optionable
• Beta: 0.80